Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Express Scripts
Baxter
McKesson
Cipla
Healthtrust
Mallinckrodt
Boehringer Ingelheim

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207318

« Back to Dashboard

NDA 207318 describes NUPLAZID, which is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the NUPLAZID profile page.

The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
Summary for 207318
Tradename:NUPLAZID
Applicant:Acadia Pharms Inc
Ingredient:pimavanserin tartrate
Patents:15
Generic Entry Opportunity Date for 207318
Generic Entry Date for 207318*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 207318
Suppliers and Packaging for NDA: 207318
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NUPLAZID pimavanserin tartrate TABLET;ORAL 207318 NDA ACADIA Pharmaceuticals Inc 63090-100 63090-100-30 30 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-100-30)
NUPLAZID pimavanserin tartrate TABLET;ORAL 207318 NDA ACADIA Pharmaceuticals Inc 63090-170 63090-170-60 60 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-170-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 17MG BASE
Approval Date:Apr 29, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 29, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Mar 6, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Mar 6, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PSYCHOSIS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fish and Richardson
Boehringer Ingelheim
Covington
Julphar
Accenture
Healthtrust
UBS
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.